Thrombocytopenia

The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.

The risk for cerebral venous sinus thrombosis within 28 days of receiving a first dose of a vector-based COVID-19 vaccine was higher in younger age groups among European populations, according to a study published in Neurology.

Aaron T. Gerds, MD, MS, speaks with Healio about the safety of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Aaron T. Gerds, MD, MS, speaks with Healio about the challenge dosing for ruxolitinib in patients with thrombocytopenia and the development of pacritinib as a Janus kinase inhibitor “specifically for patients with low platelet counts.”

Aaron T. Gerds, MD, MS, speaks with Healio about results from a retrospective analysis of data from the Persist-2 study presented at ASH Annual Meeting and Exposition.

The AGA published clinical practice guidelines in Gastroenterology for the management of coagulation disorders among patients with cirrhosis.

More than 50% of individuals with thrombosis and thrombocytopenia syndrome linked to COVID-19 vector-based vaccine administration presented with cerebral venous sinus thrombosis, according to a study.

In a case study of three patients with COVID-19 vaccine-induced immune thrombotic thrombocytopenia, starting intravenous immune globulin was linked to reduced antibody-induced platelet activation in serum, according to data.

Persistent low-to-moderate thrombocytopenia can identify patients with antiphospholipid syndrome who are at high risk for thrombosis, and is linked to poor long-term survival, according to data published in Rheumatology.

Low platelet count and intracranial hemorrhage appeared associated with increased risk for death among hospitalized patients with COVID-19 vaccine-induced immune thrombocytopenia and thrombosis, according to study results.